Quantcast

AstraZeneca’s Bevespi Aerosphere approved in Japan for COPD patients

AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.

Read more

Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .

Read more

The approval of BRACAnalysis for women with ovarian cancer in Japan

Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.

Read more

Global oligonucleotide synthesis market could reach $2.9billion by 2024

Global oligonucleotide synthesis market is expected to reach $2.9billion by 2024, at a CAGR of 10.5% during the forecast period of 2019to 2024.

Read more